Sangamo BioSciences Nominates Thomas G. Wiggans to Its Board of Directors

RICHMOND, Calif., April 28 /PRNewswire-FirstCall/ -- Sangamo
BioSciences, Inc. (Nasdaq: SGMO), a leader in the research and development
of novel zinc finger DNA-binding proteins (ZFPs) for therapeutic gene
regulation and modification, announced today the nomination of Thomas G.
Wiggans to the company's Board of Directors.

Mr. Wiggans most recently served as Chief Executive Officer of
Connetics Corporation, a biotechnology company, from 1994, and as Chairman
of the Board from January 2006, until December 2006 when Connetics
Corporation was acquired by Stiefel Laboratories, Inc. He remains an
advisor to Steifel Laboratories. From 1992 to 1994, Mr.Wiggans served as
President and Chief Operating Officer of CytoTherapeutics. From 1980 to
1992, he served in various positions at Ares-Serono Group, a pharmaceutical
company, including President of its U.S. pharmaceutical operations and
Managing Director of its U.K. pharmaceutical operations. Mr. Wiggans
currently serves as Chairman of the Board of Peplin, Inc, as a member of
the Board of Directors of Onyx Pharmaceuticals Inc., the Board of Overseers
of the Hoover Institution at Stanford University and the Board of Trustees
of the University of Kansas Endowment Association. In addition, he is
Chairman of the Biotechnology Institute, a non-profit educational
organization. Mr. Wiggans received a B.S. in Pharmacy from the University
of Kansas and an M.B.A. from Southern Methodist University.

"I am delighted to welcome Tom Wiggans to our Board of Directors," said
Edward Lanphier, Sangamo's president and CEO. "Tom's strategic and
operational experience as a senior biotechnology industry executive,
combined with his outstanding service on multiple life sciences boards,
will be invaluable to Sangamo's board and management team. We welcome him
as we continue to advance both our clinical pipeline and the broader
industry applications of our ZFP technology."

"I am very pleased to be nominated to Sangamo's board of directors,"
commented Mr. Wiggans. "Sangamo is establishing an important new
therapeutic product development platform based on their proprietary ZFP
technology. This is an exciting stage for the company as they prepare to
present their first Phase 2 data from their lead ZFP Therapeutic(TM)
program in diabetic neuropathy. I look forward to contributing my
operational experience to help position Sangamo for future growth and
success."

Mr. Wiggans will be eligible for election to the board at Sangamo's
2008 Annual Meeting when existing board members will also be under
consideration for re-election by shareholders. The meeting will be held at
9:00 am (PT) on Wednesday, June 4, 2008 at the company's headquarters in
Richmond, California.

Important Additional Information Filed with the SEC

Sangamo and its directors and officers may be deemed to be participants
in the solicitation of proxies in connection with Sangamo's 2008 Annual
Meeting of Stockholders. Sangamo will file with the SEC and mail to its
stockholders definitive proxy statement for the Annual Meeting of
Stockholders. The definitive proxy statement will contain important
information regarding the participants in the solicitation and proposals
submitted to the stockholders for approval at the Annual Meeting, including
the proposal to elect directors of Sangamo.

Stockholders of Sangamo are advised to read the definitive proxy
statement when it becomes available. Stockholders of Sangamo may obtain,
free of charge once they become available, copies of the definitive proxy
statement and other documents filed by Sangamo with the SEC at the internet
website maintained by the SEC at http://www.sec.gov. These documents may
also be obtained free of charge by calling investor relations at Sangamo at
(510) 970-6000.

About Sangamo BioSciences Inc.

Sangamo BioSciences, Inc. is focused on the research and development of
novel DNA-binding proteins for therapeutic gene regulation and
modification. The most advanced ZFP Therapeutic(TM) development program is
currently in Phase 2 clinical trials for evaluation of safety and clinical
effect in patients with diabetic neuropathy. Phase 1 clinical trials are
ongoing to evaluate a ZFP Therapeutic for peripheral artery disease. Other
therapeutic development programs are focused on stem cell mobilization,
ALS, cancer, HIV/AIDS, neuropathic pain, nerve regeneration, Parkinson's
disease and monogenic diseases. Sangamo's core competencies enable the
engineering of a class of DNA-binding proteins known as zinc finger
DNA-binding proteins (ZFPs). By engineering ZFPs that recognize a specific
DNA sequence Sangamo has created ZFP transcription factors (ZFP TF(TM))
that can control gene expression and, consequently, cell function. Sangamo
is also developing sequence-specific ZFP Nucleases (ZFN(TM)) for gene
modification. Sangamo has established strategic partnerships with companies
outside of the human therapeutic space including Dow AgroSciences,
Sigma-Aldrich Corporation and several companies applying its ZFP Technology
to enhance the production of protein pharmaceuticals. For more information
about Sangamo, visit the company's web site at http://www.sangamo.com.

This press release contains forward-looking statements regarding
Sangamo's current expectations. These forward looking statements include,
without limitation, references to the research and development of ZFP TFs
and ZFNs, clinical trials and therapeutic applications of Sangamo's ZFP
technology platform, and election of directors. These statements are not
guarantees of future performance and are subject to certain risks,
uncertainties and assumptions that are difficult to predict. Factors that
could cause actual results to differ include the early stage of ZFP
Therapeutic development, uncertainties related to the timing of initiation
and completion of clinical trials, and whether clinical trial results will
validate and support the safety and efficacy of ZFP Therapeutics. Further,
there can be no assurance that the necessary regulatory approvals will be
obtained or that Sangamo will be able to develop commercially viable gene
based therapeutics. Actual results may differ from those projected in
forward-looking statements due to risks and uncertainties that exist in the
company's operations and business environments. These risks and
uncertainties are described more fully in the company's' Annual Reports on
Form 10-K and Quarterly Reports on Form 10-Q as filed with the Securities
and Exchange Commission. Forward-looking statements contained in this
announcement are made as of this date and will not be updated.





See Also

• Free Prescription Drug Cards Offered to Support Cover the Uninsured National Campaign Events
• Terumo, Global Medical Technology Company, Opens Office in Switzerland
• Cockroaches Worsen Asthma Symptoms
• eDrugSearch.com Has Generated More than $2.1 Million in Revenues for Member Pharmacies

Via: Healthcare